BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 26906472)

  • 1. Design, synthesis, and docking studies of afatinib analogs bearing cinnamamide moiety as potent EGFR inhibitors.
    Tu Y; OuYang Y; Xu S; Zhu Y; Li G; Sun C; Zheng P; Zhu W
    Bioorg Med Chem; 2016 Apr; 24(7):1495-503. PubMed ID: 26906472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis, and docking studies of quinazoline analogues bearing aryl semicarbazone scaffolds as potent EGFR inhibitors.
    Tu Y; Wang C; Xu S; Lan Z; Li W; Han J; Zhou Y; Zheng P; Zhu W
    Bioorg Med Chem; 2017 Jun; 25(12):3148-3157. PubMed ID: 28428040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis, antiproliferative activity and docking studies of quinazoline derivatives bearing 2,3-dihydro-indole or 1,2,3,4-tetrahydroquinoline as potential EGFR inhibitors.
    OuYang Y; Zou W; Peng L; Yang Z; Tang Q; Chen M; Jia S; Zhang H; Lan Z; Zheng P; Zhu W
    Eur J Med Chem; 2018 Jun; 154():29-43. PubMed ID: 29775935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, and docking studies of phenylpicolinamide derivatives bearing 1H-pyrrolo[2,3-b]pyridine moiety as c-Met inhibitors.
    Zhu W; Wang W; Xu S; Tang Q; Luo R; Wang M; Gong P; Zheng P
    Bioorg Med Chem; 2016 Feb; 24(4):812-9. PubMed ID: 26810712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis, and docking studies of phenylpyrimidine-carboxamide derivatives bearing 1H-pyrrolo[2,3-b]pyridine moiety as c-Met inhibitors.
    Zhu W; Wang W; Xu S; Wang J; Tang Q; Wu C; Zhao Y; Zheng P
    Bioorg Med Chem; 2016 Apr; 24(8):1749-56. PubMed ID: 26964675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis, anti-tumor activity, and molecular modeling of quinazoline and pyrido[2,3-d]pyrimidine derivatives targeting epidermal growth factor receptor.
    Hou J; Wan S; Wang G; Zhang T; Li Z; Tian Y; Yu Y; Wu X; Zhang J
    Eur J Med Chem; 2016 Aug; 118():276-89. PubMed ID: 27132165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel morpholin-3-one fused quinazoline derivatives as EGFR tyrosine kinase inhibitors.
    Qin X; Lv Y; Liu P; Li Z; Hu L; Zeng C; Yang L
    Bioorg Med Chem Lett; 2016 Mar; 26(6):1571-1575. PubMed ID: 26879314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a series of novel 4-anlinoquinazoline derivatives possessing quinazoline skeleton: Design, synthesis, EGFR kinase inhibitory efficacy, and evaluation of anticancer activities in vitro.
    Chang J; Ren H; Zhao M; Chong Y; Zhao W; He Y; Zhao Y; Zhang H; Qi C
    Eur J Med Chem; 2017 Sep; 138():669-688. PubMed ID: 28711702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and biological evaluation of cinnamamide-quinazoline derivatives as potential EGFR inhibitors to reverse T790M mutation.
    Zhang B; Xu Z; Liu Q; Xia S; Liu Z; Liao Z; Gou S
    Bioorg Chem; 2021 Dec; 117():105420. PubMed ID: 34655841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel 4-arylaminoquinazoline derivatives with (E)-propen-1-yl moiety as potent EGFR inhibitors with enhanced antiproliferative activities against tumor cells.
    Chen L; Zhang Y; Liu J; Wang W; Li X; Zhao L; Wang W; Li B
    Eur J Med Chem; 2017 Sep; 138():689-697. PubMed ID: 28711703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and biological evaluation of 6-(nitroimidazole-1H-alkyloxyl)-4-anilinoquinazolines as efficient EGFR inhibitors exerting cytotoxic effects both under normoxia and hypoxia.
    Cheng W; Zhu S; Ma X; Qiu N; Peng P; Sheng R; Hu Y
    Eur J Med Chem; 2015 Jan; 89():826-34. PubMed ID: 25462282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of new HER2/EGFR dual kinase inhibitors based on the anilinoquinazoline scaffold as potential anti-cancer agents.
    Sadek MM; Serrya RA; Kafafy AH; Ahmed M; Wang F; Abouzid KA
    J Enzyme Inhib Med Chem; 2014 Apr; 29(2):215-22. PubMed ID: 23402383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis, cytotoxic evaluation, and molecular docking studies of novel quinazoline derivatives with benzenesulfonamide and anilide tails: Dual inhibitors of EGFR/HER2.
    Alkahtani HM; Abdalla AN; Obaidullah AJ; Alanazi MM; Almehizia AA; Alanazi MG; Ahmed AY; Alwassil OI; Darwish HW; Abdel-Aziz AA; El-Azab AS
    Bioorg Chem; 2020 Jan; 95():103461. PubMed ID: 31838290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of Benzo[g]quinazolin benzenesulfonamide derivatives as dual EGFR/HER2 inhibitors.
    Alsaid MS; Al-Mishari AA; Soliman AM; Ragab FA; Ghorab MM
    Eur J Med Chem; 2017 Dec; 141():84-91. PubMed ID: 29028534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting EGFR/HER2 tyrosine kinases with a new potent series of 6-substituted 4-anilinoquinazoline hybrids: Design, synthesis, kinase assay, cell-based assay, and molecular docking.
    Elkamhawy A; Farag AK; Viswanath AN; Bedair TM; Leem DG; Lee KT; Pae AN; Roh EJ
    Bioorg Med Chem Lett; 2015 Nov; 25(22):5147-54. PubMed ID: 26475520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of novel pyrrolo-pyridine/pyrimidine derivatives bearing pyridazinone moiety as c-Met kinase inhibitors.
    Wang LX; Liu X; Xu S; Tang Q; Duan Y; Xiao Z; Zhi J; Jiang L; Zheng P; Zhu W
    Eur J Med Chem; 2017 Dec; 141():538-551. PubMed ID: 29107421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and discovery of 4-anilinoquinazoline-acylamino derivatives as EGFR and VEGFR-2 dual TK inhibitors.
    Zhang HQ; Gong FH; Li CG; Zhang C; Wang YJ; Xu YG; Sun LP
    Eur J Med Chem; 2016 Feb; 109():371-9. PubMed ID: 26826581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis, molecular docking and cytotoxic evaluation of novel 2-furybenzimidazoles as VEGFR-2 inhibitors.
    Abdullaziz MA; Abdel-Mohsen HT; El Kerdawy AM; Ragab FAF; Ali MM; Abu-Bakr SM; Girgis AS; El Diwani HI
    Eur J Med Chem; 2017 Aug; 136():315-329. PubMed ID: 28505536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis and biological evaluation of novel 4-anilinoquinazolines with C-6 urea-linked side chains as inhibitors of the epidermal growth factor receptor.
    Zhang X; Peng T; Ji X; Li J; Tong L; Li Z; Yang W; Xu Y; Li M; Ding J; Jiang H; Xie H; Liu H
    Bioorg Med Chem; 2013 Dec; 21(24):7988-98. PubMed ID: 24183742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis, EGFR Inhibition and Anti-cancer Activity of New 3,6-dimethyl-1-phenyl-4-(substituted-methoxy)pyrazolo[3,4-d] pyrimidine Derivatives.
    Bakr RB; Mehany ABM; Abdellatif KRA
    Anticancer Agents Med Chem; 2017; 17(10):1389-1400. PubMed ID: 28270084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.